CoChat

Development of brain organoid technology derived from iPSC for the neurodegenerative disease modelling: a glance through

Open access
Jusop, Amirah Syamimi, Thanaskody, Kalaiselvaan, Tye, Gee Jun, Dass, Sylvia Annabel, Wan Kamarul Zaman, Wan Safwani, Nordin, Fazlina · 2023 · Frontiers in Molecular Neuroscience
Cited by 39

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Neurodegenerative diseases are adult-onset neurological conditions that are notoriously difficult to model for drug discovery and development because most models are unable to accurately recapitulate pathology in disease-relevant cells, making it extremely difficult to explore the potential mechanisms underlying neurodegenerative diseases. Therefore, alternative models of human or animal cells have been developed to bridge the gap and allow the impact of new therapeutic strategies to be anticipated more accurately by trying to mimic neuronal and glial cell interactions and many more mechanisms. In tandem with the emergence of human-induced pluripotent stem cells which were first generated in 2007, the accessibility to human-induced pluripotent stem cells (hiPSC) derived from patients can be differentiated into disease-relevant neurons, providing an unrivaled platform for in vitro modeling, drug testing, and therapeutic strategy development. The recent development of three-dimensional (3D) brain organoids derived from iPSCs as the best alternative models for the study of the pathological features of neurodegenerative diseases. This review highlights the overview of current iPSC-based disease modeling and recent advances in the development of iPSC models that incorporate neurodegenerative diseases. In addition, a summary of the existing brain organoid-based disease modeling of Alzheimer’s disease was presented. We have also discussed the current methodologies of regional specific brain organoids modeled, its potential applications, emphasizing brain organoids as a promising platform for the modeling of patient-specific diseases, the development of personalized therapies, and contributing to the design of ongoing or future clinical trials on organoid technologies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnmol.2023.1173433

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 39

Metadata

Authors
Jusop, A. S., Thanaskody, K., Tye, G. J., Dass, S. A., Wan Kamarul Zaman, W. S., & Nordin, F.
Venue
Frontiers in Molecular Neuroscience
Published
2023-08-03
Volume
16
Pages
1173433-1173433
ISSN
1662-5099 (ISSN-L)
OpenAlex
W4385546433
Cited by
39
References
25
FWCI
2.91
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of brain organoid technology derived from iPSC for the neurodegenerative disease modelling: a glance through. https://app.cochat.ai/papers/10.3389/fnmol.2023.1173433
The paper
Jusop, A. S., Thanaskody, K., Tye, G. J., Dass, S. A., Wan Kamarul Zaman, W. S., & Nordin, F. (2023). Development of brain organoid technology derived from iPSC for the neurodegenerative disease modelling: a glance through. Frontiers in Molecular Neuroscience. https://doi.org/10.3389/fnmol.2023.1173433

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.